Monthly Archives: January 2007

Reconsidering psychiatric drugs

The Register Guard (Eugene, Oregon)

By Susan Palmer

When the anti-psychotic drug Zyprexa came into Tracey Dumas’ life five years ago, it sounded like a good thing: a relatively new medication that would relieve her psychotic thoughts without the damaging side effects of the old drugs. Dumas was willing to try it.

But like many of the powerful class of neuroleptics that target the symptoms of mental illness, Zyprexa had problems. After a year of taking it, the normally petite Dumas had gained 90 pounds and had developed pre-diabetic symptoms, an illness that did not run in her family.

While the drug seemed to calm her delusional thoughts and didn’t make her feel as sluggish as some other medications, it was also ruining her health.

Now, like thousands of others, Dumas is part of a class-action lawsuit against Zyprexa manufacturer Eli Lilly, which already has spent $1.4 billion to settle more than 20,000 claims by patients who say the drug made them sick.

Oregon Attorney General Hardy Myers is one of five attorneys general investigating whether Eli Lilly illegally promoted uses of Zyprexa that have not been approved by the U.S. Food and Drug Administration…


Leave a comment

Filed under Uncategorized

Madigan turns up heat on disputed Zyprexa lawsuit

by Rob Luke

SPRINGFIELD — Illinois attorney general Lisa Madigan has ratcheted up the pressure on pharmaceutical giant Eli Lilly over a controversial drug-marketing lawsuit that has drawn fire from reform advocates.

Lawyers at the consumer protection division of the Illinois attorney general’s office last week demanded that company officials hand over documents concerning the marketing of Zyprexa, Lilly’s blockbuster mental health drug. Their counterparts in the Vermont AG’s office have joined the action.

A five-state legal action against Eli Lilly alleges the company tried to cover up negative side-effects of Zyprexa and that it tried to market the drug for disorders other than its scheduled treatment for schizophrenia and bipolar disorder. Such “off-label” prescription is a violation of federal law…

Leave a comment

Filed under Uncategorized